The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage

Arthritis Research and Therapy

Volumn 15, Issue SUPPL 3, 2013, Pages

  Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; ESOMEPRAZOLE; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ATTRIBUTABLE RISK; CARDIOVASCULAR RISK; DRUG HYPERSENSITIVITY; DUODENUM ULCER; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PEPTIC ULCER; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT PEPTIC ULCER; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STOMACH ACID SECRETION; STOMACH MUCOSA INJURY; STOMACH ULCER; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GASTROINTESTINAL DISEASE; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; INTESTINE MUCOSA; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINAL MUCOSA; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84880705961     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4177     Document Type: Review

References (31)

1. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986, 1:489-492.
2. Jones R, Rubin G, Berenbaum F, Scheiman J. Protection of the upper gastrointestinal tract in patients taking nonsteroidal anti-inflammatory drugs. Am J Med 2008, 121:464-474.
3. Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004, 329:867-868.
4. Scheiman JM. NSAIDs, cytoprotection, and gastrointestinal injury. Gastroenterol Clin North Am 1996, 25:279-298.
5. Rostom A, Dube C, Wells GA, Tugwell P, Welch V, Jolicoeur E, McGowan J, Lanas A. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, 4:CD002296.
6. Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009, 69:51-69.
7. Lancaster Smith MJ, Jadeberg ME, Jackson DA. Ranitidine in the treatment of non steroidal antiinflammtory drug associated gastric and duodenal ulcer. Gut 1991, 32:252-255.
8. Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relaspe rates in patients with benign gastric ulcer. N Engl J Med 1989, 320:69-75.
9. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal antiinflammtory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000, 160:1455-1461.
10. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734.
11. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: a systematic review. BMJ 2004, 329:948.
12. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX 2 inhibitors. Am J Gastroenterol 2006, 101:701-710.
13. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Chung SC, Sung JJ. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
14. Lai KC, Chu KM, Hui WM, Wong BCY, Hu HC, Wong WM, Chan AOO, Wong J, Lam SK. Celecoxib compared to lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005, 118:1271-1278.
15. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, Aleman S, Nicolas D, Feu F, González-Pérez A, Borda A, Castro M, Poveda MJ, Arenas J, Investigators of the Asociación Española de Gastroenterología Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007, 102:507-515. Investigators of the Asociación Española de Gastroenterología.
16. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR. Risk of peptic ulcer hospitalizations in users of NSAIDS within gastroprotective cotherapy versus coxibs. Gastroenterology 2007, 133:790-798.
17. Chan FKL, Wong VWS, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH, Wong GL, Chow DK, To KF, Leung WK, Chiu PW, Lee YT, Lau JY, Chan HL, Ng EK, Sung JJ. Combination of a cyclooxygenase-2 inhibitor and a proton pump inhibitor for the prevention of recurrent ulcer bleeding in patients with very high gastrointestinal risk: a double-blind, randomized trial. Lancet 2007, 369:1621-1626.
18. Metge CJ, Leung S, Chateau DG. The relative efficiacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008, 134:937-944.
19. Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
20. Chan FK, Chung S, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspiring or naproxen. N Engl J Med 2001, 344:967-973.
21. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167-180. European Helicobacter Pylori Study Group.
22. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
23. Van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007, 26:265-275.
24. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
25. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008, 103:2908-2918.
26. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M, EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681. EULAR Standing Committee for International Clinical Studies Including Therapeutics.
27. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
28. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
29. Osteoarthritis. The Care and Management of Osteoarthritis in Adults., http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf
30. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007, 369:1580-1581.
31. Scheiman JM. Balancing risks and benefits of cyclooxygenase-2 selective NSAIDs. Gastroenterol Clin North Am 2009, 38:305-314.